Aeon Biopharma Inc. (AEON)
AMEX AMEX Primary Summary
AEON Biopharma, Inc. (AEON) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
AEON Biopharma, Inc. (AEON) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Down -64.16% in 4 Weeks, Here's Why AEON Biopharma, Inc. (AEON) Looks Ripe for a Turnaround
AEON Biopharma, Inc. (AEON) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Aeon Biopharma Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| ABB Alexander Bjornager Bonde Danske Bank A/S | 1 | $0.58 | $0.28 | -$0.3 | -51.72% |
| HFT Hui Fai Tam Caitong International Asset Management Co. Ltd. | 1 | $1 | $0.29 | -$0.71 | -71% |
 Matthew Okkerse Dauntless Investment Group LLC | 2.53M | $2.17M | $712,074.22 | -$1.46M | -67.15% |
Aeon Biopharma Inc. (AEON) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Aeon Biopharma Inc. ever had a stock split?
Aeon Biopharma Inc. Profile
| Biotechnology Industry | Healthcare Sector | Robert Bancroft CEO | AMEX Exchange | 00791X209 CUSIP |
| US Country | 8 Employees | - Last Dividend | 26 Feb 2025 Last Split | - IPO Date |
Overview
AEON Biopharma, Inc. is a clinical stage biopharmaceutical company dedicated to advancing the field of botulinum toxin therapy. Based in Irvine, California, AEON focuses on leveraging its expertise in botulinum toxins to develop treatments for various debilitating medical conditions. With a strong commitment to improving patients' lives, AEON's research and development activities are at the forefront of unlocking the therapeutic potential of botulinum toxins.
Products and Services
- ABP-450 (prabotulinumtoxinA) Injection for Cervical Dystonia:
This product has completed a Phase 2 study, showcasing AEON Biopharma's dedication to addressing the needs of patients suffering from cervical dystonia. The development of ABP-450 represents a significant step forward in providing an effective treatment option for this debilitating condition.
- ABP-450 for Chronic and Episodic Migraine:
Currently in an ongoing Phase 2 study, ABP-450 is being explored as a treatment for both chronic and episodic migraine. This endeavor demonstrates AEON's commitment to tackling one of the most common and challenging neurological disorders, potentially offering relief to millions of individuals experiencing migraine headaches.
- ABP-450 for Gastroparesis:
In its developmental stages for treating gastroparesis, ABP-450 aims to provide a solution for this complex gastric motility disorder. Through targeting this condition, AEON Biopharma is addressing an area of significant unmet medical need, underlining its mission to develop botulinum toxin treatments for a range of medical issues.
- ABP-450 for Posttraumatic Stress Disorder (PTSD):
Expanding its research into neuropsychiatric conditions, AEON is developing ABP-450 for the treatment of PTSD. This effort reflects the company's innovative approach to leveraging botulinum toxins beyond traditional applications, potentially offering a novel and effective therapy for individuals suffering from PTSD.
